Lumida
/GOSS
⌘K
Gossamer Bio Inc

Gossamer Bio Inc

GOSS
$0.17USD↓-0.23%-0.00 today

MARKET CAP

83.2M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$0 – $0

52W RANGE

$0
$4

AI Summary

Stalk
Sell NowMedium

GOSS remains in a Stage 4 decline with both long- and short-term downtrends intact. Price continues to trade below the 9, 21, 50, and 200 EMAs, with repeated rejections at those levels. The active Post-Capitulation pattern shows forced selling has exhausted but no base has formed, reinforcing a bearish medium-term stance. Short-term momentum and EMA rejection favor immediate downside participation, warranting a sell-now posture despite oversold context.

  • ↑Serolutinib improved six-minute walk distance by 28.2m vs. 13.5m placebo.
  • ↑$99M cash runway supports operations into Q1 2027.
  • ↓Earnings yield sits at -3.27, undermining return prospects.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Gossamer Bio, Inc. (NASDAQ: GOSS) is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients suffering from serious diseases, particularly pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). The company focuses on serolutinib, an inhaled kinase inhibitor aimed at providing unique therapeutic benefits through a differentiated mechanism of action. Positioned within the vibrant biopharmaceutical sector, Gossamer Bio is exploring the frontiers of pulmonary and gastrointestinal diseases, due to the high unmet medical needs in these areas.

Bull says

  • ↑Serolutinib improved six-minute walk distance by 28.2m vs. 13.5m placebo.
  • ↑$99M cash runway supports operations into Q1 2027.
  • ↑Convertible debt cut from $200M to $72M with extended maturities.
  • ↑Type B pre-NDA meeting secured; NDA filing targeted Sep 2026.
  • ↑Clinical community sees potential serolutinib use across PAH patients.
  • ↑Strong institutional backing and positive momentum boost outlook.

Bear says

  • ↓Earnings yield sits at -3.27, undermining return prospects.
  • ↓Growth revisions have turned negative, reflecting weak analyst sentiment.
  • ↓High leverage ratio elevates financial vulnerability amid rising rates.
  • ↓FDA approval risk could delay or derail serolutinib launch.
  • ↓Competition from UTHR, AMGN, JNJ and PFE challenges market share.
  • ↓Operating costs remain high despite workforce reductions.

Investment themes with GOSS

Biotech↑ +0.07%

Genetic and drug innovations driving medical breakthroughs

ABBV · AMGN · TMO
Most Shorted Stocks↑ +0.54%

Stocks with highest short interest

LITE · FSLY · SPHR
Julian Komar's Best Winners (Screen Results)↓ -0.50%

NVDA · GOOGL · AVGO

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-19-2026bullish

Transcript signals

Bull points

  • Our conviction in serolutinib has increased since the top line readout, not decreased. That conviction is based on a totality of evidence, consistent drug arm performance in ProSERA, confirmatory data from Tori, multi-compartment mechanistic evidence from the CT-FRI and the regulatory path we're advancing with the FDA.
  • We now have a confirmed Type B pre-NDA meeting and expect to submit the NDA in September of 2026.
  • Taken together with Phase III ProSERA data and the Phase II TORI data, we believe the overall evidence supports an NDA path for seraludinib.

Bear points

  • we engaged constructively with our convertible note holders to address the upcoming 2027 maturity.
Read full transcript analysis ›